Abstract:Anaplastic lymphoma kinase (ALK) fusion genes promote a variety of human malignancies. Although several ALK inhibitors have significantly improved disease prognosis in patients with ALK positive cancers, the persistent emergence of acquired drug-resistant mutations remain the major problem in clinic treatment. Adoption of new therapeutic strategies such as proteolysis targeting chimera (PROTAC) to overcome drug resistance in BTK/AR-related cancers have shown promising prospect. Herein, we reported the integrate ALK PROTACs through overall optimization of linker, revealed that subtle structural differences can lead to significant activity difference, indicating the key role of conformation of PROTACs in inducing the formation of E3-PROTAC-target protein ternary complexes. A series of rigid ALK PROTACs were developed through conjugation of Ceritinib and thalidomide, orally bioavailable PROTAC 4B (F = 14.22%) was obtained by overall optimization of molecular properties. 4B effectively induced long lasting degradation of ALK fusion proteins and strong repression of downstream pathway in Karpas 299 cells (DC 50 = 119.33 nM, Dmax = 97.1%) and showed comparable anti-proliferative activity to Ceritinib (IC 50 = 3.11 ± 0.08 nM vs IC 50 = 1.31 ± 0.43 nM). Furthermore, 4B significantly inhibited the growth of Karpas 299 xenografts in vivo with TGI of 49.5% and showed superior anti-proliferative activity against G1202R mutation to Ceritinib (IC 50 = 52.82 nM vs IC 50 = 109.5 nM). Overall, 4B is expected to be a potential treatment for ALK-driven malignancies.

Novel Tetracyclic Benzo[b]carbazolones As Highly Potent and Orally Bioavailable ALK Inhibitors: Design, Synthesis, and Structure-Activity Relationship Study.

Metabolism-Based Structure Optimization: Discovery of A Potent and Orally Available Tyrosine Kinase Alk Inhibitor Bearing the Tetracyclic Benzo[B]Carbazolone Core

An Orally Available Tyrosine Kinase Alk and Ret Dual Inhibitor Bearing the Tetracyclic Benzo[B]Carbazolone Core

Synthesis and Biological Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as Selective ALK5 Inhibitors

Synthesis and Biological Evaluation of Novel Benzo[c] [1,2,5]Thiadiazol-5-yl and Thieno [3,2-C] - Pyridin-2-yl Imidazole Derivatives As ALK5 Inhibitors

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis and Biological Evaluation of 4-(Pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole Derivatives As Novel Potent Transforming Growth Factor-Β Type 1 Receptor Inhibitors.

Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects

Design, Synthesis and Pharmacological Evaluation of 2-(Thiazol-2-amino)-4-arylaminopyrimidines As Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors

Design, Synthesis and Biological Evaluation N2-(2-alkyoxy-6-aliphatic Aminopyridin-3-yl)-2,4-diaminepyrimidine Derivatives Bearing Acylamino or DBTD ‘head’ As Potential ALK Inhibitors

Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Design, Synthesis and Biological Evaluation of Β-Carboline Derivatives As Novel Inhibitors Targeting B-Raf Kinase

Identification and Anti-Tumor Evaluation of 3-Acyl-indol-based 2,4-Diarylaminopyrimidine Analogues As Potent ALK Inhibitors Capable of Overcoming Drug-Resistant Mutants.

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives As Potent C-Met Kinase Inhibitor

Design and Synthesis of Pyrido[3,2-Α]carbazole Derivatives and Their Analogues As Potent Antitumour Agents.

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Design, synthesis, and biological evaluation of 4-aryl-9 H -carbazoles as tubulin polymerization inhibitors with potent anticancer activities